Skip to main content
. Author manuscript; available in PMC: 2018 Jan 16.
Published in final edited form as: Clin Cancer Res. 2016 Dec 30;23(12):3109–3119. doi: 10.1158/1078-0432.CCR-16-1508

Figure 4. JAK 1/2 inhibition prevents low to high-grade tumor progression.

Figure 4

(A) Animal schematic depicting experimental design to examine effect of AZD1480 (treatment for 3 weeks) on tumor progression. Treatment with AZD1480 was stopped at 6 weeks (B) Representative images of T2-weighted 7T MRI of vehicle control (n=9) and AZD1480(n=9) treated animals at 6 weeks. Representative images of H&E staining of tumor sections from control (n=8) and AZD1480 (n=8) treated animals at 6 weeks, Scale Bar 100 μm. (C) Representative flow cytometry graphs of CD11b+/GR1+ from blood (n=3/group) and bone marrow (n=7/group) of vehicle control and AZD1480 treated tumor bearing mice at 6 weeks, *p=0.0386 blood, p=0.0556 BM (D) Kaplan-Meier symptom free survival curve for RCAS mice treated for 3 weeks only with vehicle control (n=9) and AZD1480,(n=9) *** P<0.0001.(E) Kaplan-Meier symptom free survival curve for RCAS mice treated indefinitely with vehicle control(n=6) and AZD1480(n=6), ***p<0.0001.